
Not actual patient.


Not actual patient.

Cisplatin is a powerful medicine used to treat cancer. Over time, cisplatin builds up in the cochlea (cok-lee-ah), the spiral-shaped part of the inner ear.
As it builds up in the cochlea, cisplatin can permanently damage the hair cells that make sound louder. Once those cells are gone, they don’t come back.
For many, hearing loss becomes a lifelong reminder of what cancer took—and what treatment left behind.



*Based on Chang grading scale. Prevalence may differ based on alternate grading scales.

Cochlear damage can begin early and continue even after cisplatin treatment ends. A person may begin to not hear higher-pitched sounds like music or birds. Later, they may not hear lower-pitched sounds like thunder. That’s why it’s important they get their hearing tested before, during, and after treatment.
Symptoms and responses to any treatment may vary, so it’s important to talk with a healthcare provider about what is the right treatment plan and to follow the doctor’s recommendations.
Unlike other effects of cancer treatment, hearing loss doesn’t return with time. It’s not just sound that’s lost, it’s how we move in the world.

Speech and language skills

Social-emotional development

Academic performance

Career potential

Ability to live independently

Academic performance
Fennec HEARS™ is the single source for both financial and patient support. Call 855-615-7946.


Find helpful tools and resources.
Please see full Prescribing Information, including Patient Information, for PEDMARK.
PEDMARK is a prescription medicine used to decrease the risk of hearing loss in children 1 month of age and older who are receiving cisplatin for solid tumors (cancer) that have not spread to other parts of the body.
It is not known if PEDMARK is safe and effective when given after cisplatin infusions longer than 6 hours.
It is not known if PEDMARK is safe and effective in children less than 1 month of age. PEDMARK is not recommended in children younger than 1 month of age.